<table>
<thead>
<tr>
<th>Study</th>
<th>PI</th>
<th>Abstract</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>TELESTAR</td>
<td>Martyn Caplin</td>
<td>Abstract: Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). Kulke et al, European Cancer Congress 2015; 37LBA (29/09/2015)</td>
<td></td>
</tr>
<tr>
<td>[NCRN502]</td>
<td></td>
<td>Publication:</td>
<td></td>
</tr>
<tr>
<td>[NCRN328]</td>
<td></td>
<td>Publication:</td>
<td></td>
</tr>
<tr>
<td>[NCRN333]</td>
<td></td>
<td>Publication:</td>
<td></td>
</tr>
<tr>
<td>[NCRN379]</td>
<td></td>
<td>Publication:</td>
<td></td>
</tr>
<tr>
<td>[NCRN 12919]</td>
<td></td>
<td>Publication:</td>
<td></td>
</tr>
<tr>
<td>[NCRN239]</td>
<td></td>
<td>Publication:</td>
<td></td>
</tr>
</tbody>
</table>